Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

Pre-Market: $199.63 -0.84 (-0.42%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

by Zacks Equity Research

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Mark Vickery headshot

Top Stock Reports for Amazon, UnitedHealth & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), UnitedHealth (UNH) and AbbVie (ABBV).

Kinjel Shah headshot

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

by Kinjel Shah

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

by Zacks Equity Research

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $73.40 in the latest trading session, marking a +0.94% move from the prior day.

Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

by Zacks Equity Research

Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger

by Kinjel Shah

AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

by Sejuti Banerjea

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Sweta Killa headshot

AbbVie to Buy Allergan: Prescribed ETFs

by Sweta Killa

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

Company News For Jun 26, 2019

by Zacks Equity Research

Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION

AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal

by Zacks Equity Research

AbbVie (ABBV) offers nearly $63 billion to acquire Botox-maker Allergan to diversify its product portfolio.

The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene

Daniel Laboe headshot

AbbVie + Allergan: Where Are The Synergies?

by Daniel Laboe

AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end. AbbVie just made a $63 billion deal to acquire Dublin-based Allergan (AGN) in an attempt to keep their drive alive.

Zachary Stutler headshot

AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement

by Zachary Stutler

AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.

Abbvie Decides to Acquire Allergan

by Zacks Equity Research

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

by Mark Vickery

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study

by Zacks Equity Research

AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.

Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo

by Zacks Equity Research

Zacks.com featured highlights include: Crocs, Brinker, Shoe Carnival, AbbVie and Criteo

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $78.45 in the latest trading session, marking a -0.42% move from the prior day.

Sanghamitra Saha headshot

Forget Bargain Hunting: Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

by Zacks Equity Research

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

by Zacks Equity Research

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Top Ranked Income Stocks to Buy for June 21st

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 21st.

Is AbbVie (ABBV) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.